Pacira BioSciences, Inc.

NasdaqGS:PCRX Stok Raporu

Piyasa değeri: US$923.9m

Pacira BioSciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Pacira BioSciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

22.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi22.2%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • May 19

Pacira BioSciences: Exparel Still Supports My Original Bull Case

Summary PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That’s why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX’s overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others. Fortunately, PCRX’s recent pullback actually offers a discount on a relatively improved company compared to the first time I covered it. As such, I reiterate my “Buy” on PCRX. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 01

PCRX: Real World Procedure Data Will Support Future Upside Repricing

Analysts nudged their price target on Pacira BioSciences up by $2, citing slightly stronger modeled revenue growth of 17.50% and an 8.33% profit margin outlook, supported by recent real world data updates and mixed but active coverage on the stock. Analyst Commentary Recent research has been mixed, but the latest commentary highlights that bullish analysts are still finding reasons to lean constructive on Pacira BioSciences, especially around the updated revenue growth and margin framework that underpins the new price target.
Anlatı Güncellemesi • Apr 16

PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook

Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.
Anlatı Güncellemesi • Apr 01

PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside

Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.
Anlatı Güncellemesi • Mar 17

PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside

Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).
Anlatı Güncellemesi • Mar 03

PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure

Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.
Anlatı Güncellemesi • Feb 17

PCRX: Asia Partnership Will Drive Future Upside Potential

Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.
Anlatı Güncellemesi • Feb 02

PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential

Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).
Anlatı Güncellemesi • Jan 19

PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential

Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.
Analiz Makalesi • Jan 17

Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive

Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders won't be pleased to see that the share price has had a very rough...
Anlatı Güncellemesi • Jan 05

PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential

Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.
Anlatı Güncellemesi • Dec 14

PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential

Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).
Analiz Makalesi • Nov 13

Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality

When companies post strong earnings, the stock generally performs well, just like Pacira BioSciences, Inc.'s...
Anlatı Güncellemesi • Aug 17

Policy Changes And Partnerships Will Expand Ambulatory Market Reach

The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.
Analiz Makalesi • Jun 11

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Apr 09

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

Summary PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX’s PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. I also like how PCRX reached important patent settlements that secure its competitive prospects with Exparel’s exclusivity until 2030. In my view, PCRX remains undervalued at these levels, which is why I consider it a “Buy” despite its inherent biotech risks. Read the full article on Seeking Alpha
Analiz Makalesi • Apr 07

Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough

You may think that with a price-to-sales (or "P/S") ratio of 1.5x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...
Seeking Alpha • Mar 14

Pacira BioSciences: Back On An Uptrend After Positive Developments

Summary Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act. Pacira's new five-point plan aims for growth, profitability, and pipeline expansion, positioning it for potential blockbuster revenue and market leadership. The positive steps PCRX has taken since my last note means there is no change to my “buy” thesis. Read the full article on Seeking Alpha
Analiz Makalesi • Jan 30

Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analiz Makalesi • Jan 03

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

You may think that with a price-to-sales (or "P/S") ratio of 1.2x Pacira BioSciences, Inc. ( NASDAQ:PCRX ) is a stock...
Seeking Alpha • Nov 25

Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses

Summary Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats. The market may be a little too pessimistic - Vertex's drug is unproven in the market while generics may be held off for many more years. EXPAREL's peak years may still be ahead - PCRX stock could recoup some deserved value if it can share positive Q4 earnings, update on legal matters, and keep developing its pipeline. Read the full article on Seeking Alpha
User avatar
Yeni Anlatı • Sep 24

EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges

Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.
Analiz Makalesi • Sep 06

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

To the annoyance of some shareholders, Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shares are down a considerable 34% in...
Analiz Makalesi • Jul 23

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders that were waiting for something to happen have been dealt a blow...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PCRX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PCRX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Pacira BioSciences Piyasaya Karşı Temettü Getirisi
PCRX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (PCRX)n/a
Pazarın Alt %25'i (US)1.4%
Pazarın En İyi %25'i (US)4.3%
Sektör Ortalaması (Pharmaceuticals)2.1%
Analist tahmini (PCRX) (3 yıla kadar)n/a

Önemli Temettü: PCRX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PCRX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PCRX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PCRX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 21:40
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Pacira BioSciences, Inc. 29 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jenna DavidnerBarclays
Anita DushyanthBerenberg
Gary NachmanBMO Capital Markets Equity Research